[go: up one dir, main page]

MX2007008227A - Prevencion de trastornos tromboticos con compuestos de vitamina d activa o mimeticos de los mismos. - Google Patents

Prevencion de trastornos tromboticos con compuestos de vitamina d activa o mimeticos de los mismos.

Info

Publication number
MX2007008227A
MX2007008227A MX2007008227A MX2007008227A MX2007008227A MX 2007008227 A MX2007008227 A MX 2007008227A MX 2007008227 A MX2007008227 A MX 2007008227A MX 2007008227 A MX2007008227 A MX 2007008227A MX 2007008227 A MX2007008227 A MX 2007008227A
Authority
MX
Mexico
Prior art keywords
active vitamin
animal
thrombotic disorders
mimic
mimics
Prior art date
Application number
MX2007008227A
Other languages
English (en)
Inventor
John G Curd
Bradford S Goodwin
William David Henner
Tomasz M Beer
Original Assignee
Novacea Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacea Inc filed Critical Novacea Inc
Publication of MX2007008227A publication Critical patent/MX2007008227A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere a un metodo para prevenir, tratar, o aliviar trastornos tromboticos en un animal que comprende administrar al animal un compuesto de vitamina D activa o un mimetico del mismo. De acuerdo con la invencion, el compuesto de vitamina D activa o el mimetico del mismo se puede administrar por HDPA de modo que altas dosis del compuesto de vitamina D activa o mimetico del mismo se pueden administrar a un animal sin inducir hipercalcemia sintomatica severa. La invencion tambien se refiere a un metodo para prevenir, tratar, o aliviar trastornos tromboticos en un animal que comprende administrar al animal un compuesto de vitamina D activa o un mimetico del mismo en combinacion con uno o mas de otros agentes terapeuticos.
MX2007008227A 2005-01-05 2006-01-05 Prevencion de trastornos tromboticos con compuestos de vitamina d activa o mimeticos de los mismos. MX2007008227A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64113705P 2005-01-05 2005-01-05
US72113005P 2005-09-28 2005-09-28
PCT/US2006/000181 WO2006074226A2 (en) 2005-01-05 2006-01-05 Prevention of thrombotic disorders with active vitamin d compounds or mimics thereof

Publications (1)

Publication Number Publication Date
MX2007008227A true MX2007008227A (es) 2007-09-11

Family

ID=36648140

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007008227A MX2007008227A (es) 2005-01-05 2006-01-05 Prevencion de trastornos tromboticos con compuestos de vitamina d activa o mimeticos de los mismos.

Country Status (9)

Country Link
US (1) US20070037779A1 (es)
EP (1) EP1833485A2 (es)
JP (1) JP2008526856A (es)
AU (1) AU2006204091A1 (es)
BR (1) BRPI0606393A2 (es)
CA (1) CA2593982A1 (es)
MX (1) MX2007008227A (es)
NO (1) NO20074018L (es)
WO (1) WO2006074226A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1461044A4 (en) * 2001-12-03 2007-06-13 Novacea Inc PHARMACEUTICAL COMPOSITIONS COMPRISING ACTIVE COMPOUNDS OF VITAMIN D
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
AU2003295773A1 (en) * 2002-11-21 2004-06-18 Novacea, Inc. Treatment of liver disease with active vitamin d compounds
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
AU2004247108A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc Treatment of immune-mediated disorders with active vitamin D compounds alone or in combination with other therapeutic agents
WO2005016872A1 (en) * 2003-06-11 2005-02-24 Novacea, Inc. Treatment of lung cancer with active vitamin d compounds in combination with other treatments
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
EP1631146A4 (en) * 2003-06-11 2006-12-06 Novacea Inc TREATMENT OF CANCER USING ACTIVE VITAMIN COMPOUNDS ASSOCIATED WITH RADIOTHERAPEUTIC AGENTS AND TREATMENTS
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
WO2005117542A2 (en) * 2004-05-10 2005-12-15 Novacea, Inc. Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
KR20070038460A (ko) * 2004-05-10 2007-04-10 노바세아, 인크. 활성 비타민 디(ｄ) 화합물을 이용한 동맥 재협착의 예방
JP2009513567A (ja) * 2005-09-26 2009-04-02 ノバセア インコーポレイティッド 活性ビタミンｄ化合物を用いた化学療法又は放射線療法に関連する胃腸及び膀胱の疾患の予防及び治療
US20100209536A1 (en) * 2006-09-26 2010-08-19 The Brigham And Women's Hospital, Inc. Methods and Kits for Use in the Treatment and Prevention of Diseases or Conditions of the Immune System or Infectious Diseases
EP2129382A4 (en) * 2007-02-21 2011-01-19 Univ Michigan COMPOSITIONS AND METHODS FOR HEART MUSCLE PREVENTION
WO2011024208A1 (en) * 2009-08-24 2011-03-03 Colotech A/S Combination dosage form with acetylsalicylic acid, calcitriol and calcium
FI20135701A7 (fi) * 2013-06-26 2014-12-27 Mas Metabolic Analytical Services Oy Farmaseuttisesti käyttökelpoinen ja turvallinen kombinaatio käytettäväksi merkittävien sairauksien hoidossa
JP7595413B2 (ja) 2016-11-30 2024-12-06 ケース ウエスタン リザーブ ユニバーシティ １５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用
CA3052466A1 (en) 2017-02-06 2018-08-09 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
JP2020526579A (ja) 2017-06-29 2020-08-31 スカイライン バイオサイエンシズ，エルエルシー イソトレチノイン口腔粘膜製剤及びその使用方法
CN113507931B (zh) 2018-11-21 2025-05-27 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0946507T3 (da) * 1996-12-10 2004-01-26 Searle & Co Substituerede pyrrolylforbindelser til behandling af inflammation
ATE515265T1 (de) * 1998-03-27 2011-07-15 Univ Oregon Health & Science Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
KR20070038460A (ko) * 2004-05-10 2007-04-10 노바세아, 인크. 활성 비타민 디(ｄ) 화합물을 이용한 동맥 재협착의 예방
US20080069814A1 (en) * 2005-01-05 2008-03-20 Novacea, Inc. Prevention of Thrombotic Disorders with Active Vitamin D Compounds or Mimics Thereof

Also Published As

Publication number Publication date
WO2006074226A3 (en) 2006-11-16
CA2593982A1 (en) 2006-07-13
US20070037779A1 (en) 2007-02-15
WO2006074226A2 (en) 2006-07-13
EP1833485A2 (en) 2007-09-19
AU2006204091A1 (en) 2006-07-13
BRPI0606393A2 (pt) 2009-06-23
JP2008526856A (ja) 2008-07-24
NO20074018L (no) 2007-10-02

Similar Documents

Publication Publication Date Title
MX2007008227A (es) Prevencion de trastornos tromboticos con compuestos de vitamina d activa o mimeticos de los mismos.
WO2008005560A3 (en) Prevention of thrombotic disorders with active vitamin d compounds
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2009039460A3 (en) Co-administration of pimavanserin with other agents
AR109170A2 (es) Esfingomielinasa ácida para uso en la prevención o el tratamiento de la enfermedad de niemann-pick a o b en un paciente
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
WO2007038428A3 (en) Prevention and treatment of gastrointestinal and bladder disorders using active vitamin d compounds
PT1485080E (pt) Utilização de adapaleno para o tratamento de desordens dermatológicas
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
TW200612892A (en) Novel compounds
MY145074A (en) Thiazolidin-4-one derivatives
NO20051545L (no) Ostrogenerstatningsregime
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
MX2024002360A (es) Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales.
UA92894C2 (ru) Способ приготовления и применения композиции адсорбента фосфата, адсорбент фосфата, композиция адсорбента фосфата
WO2005117542A3 (en) Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
BRPI0414822A (pt) método de inibir a produção de lipoproteìna remanescente
PH12013500371A1 (en) Therapeutic agent for pain
PT1656131E (pt) Utilização de betaína para tratar claudicação intermitente
WO2020141828A3 (en) Anticancer compositions comprising immune checkpoint inhibitors
CL2004000765A1 (es) Composicion farmaceutica intranasal que comprende un compuesto derivado de 8,9-dioxo-2,6-diazabiciclo.
BR112014014805A2 (pt) processos para tratamento e prevenção de constipação induzida por opióide que utilizam composições orais de metilnaltrexona
AU2003239813A1 (en) Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori
EA200100930A1 (ru) Способ лечения хозл

Legal Events

Date Code Title Description
FA Abandonment or withdrawal